Abstract
Dünya genelinde ekstrapiramidal semptomların ikinci nedeni ilaçlarla indüklenen parkinsonizmdir ve toplumun yaşlanması ve polifarmasinin artması nedeniyle prevelansı idiyopatik parkinson hastalığına yaklaşmaktadır. İlaçlarla indüklenen parkinsonizm ilk olarak psikiyatrik hastalarda nöroleptik kullanımının bir komplikasyonu şeklinde ortaya çıkmıştır, ancak sonraları antiepileptikler, antimanikler, antiemetikler ve kalsiyum kanal blokörleri gibi birçok bileşik için de bildirilmiştir. İlaçlarla indüklenen parkinsonizm çoğunlukla geri dönüşlü olsa da, ilacın bırakılmasından sonra kalıcı da olabilir. İlaçlarla indüklenen parkinsonizm hastaların en azından %10'unda kalıcı ve progresif parkinsonizm gelişimine neden olabilir. İlaçlarla indüklenen parkinsonizmi tedavi etmenin en iyi yolu, bu duruma neden olan ilaçların kesinlikle gerekli olmadıkça kullanımlarına engel olmaktır. Bu derleme parkinsonizmi indükleyen ilaçlara (nöroleptikler, kalsiyum kanal blokörleri, valproat, lityum ve metoklopramid) ve olası toksikolojik sonuçlarına odaklanacaktır.
Keywords
ANAHTAR KELşMELER: şlaçla indüklenen parkinsonizm Parkinson hastal×ù× Nöroleptikler Antiepileptikler Kalsiyum kanal blokörleri
References
- Bjarkam CR, Sİrensen JC, Sunde NA, Geneser FA, Oster- gaard K. New strategies for the treatment of Parkinson’s disease hold considerable promise for the future mana- gement of neurodegenerative disorders. Biogerontology 2001;2(3):193-207.
- Gárdián G, Vécsei L. Medical treatment of Parkinson’s disease: today and the future. Int J Clin Pharmacol Ther 2010;48(10):633-642.
- Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Prog Brain Res 2010;184:133-157.
- Langston WJ. The Impact of MPTP on Parkinson’s Dise- ase Research: Past, Present, and Future. In: Parkinson’s Disease. Diagnosis and Clinical Management. Editors: Stewart A. Factor and William J. Weiner, Demos Medical Publishing. New York. 2002, pp. 299-329.
- Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, Rungger G, Gasperi A, Willeit J, Poewe W. Prevalen- ce of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4(12):815-820.
- Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, Cardoso F. Parkinsonism and Parkinson’s disease in the elderly: a community- based survey in Brazil (the Bambuí study). Mov Disord 2006;21(6):800-808.
- Kuzuhara S. [Drug-induced parkinsonism]. Nippon Rinsho 1997;55(1):112-117.
- Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM; Neurological Disorders in Cent- ral Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly popula- tions of central Spain. Mov Disord 2003;18(3):267-274.
- Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, Walker A. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995;99(1):48-54.
- Mintzer J, Targum SD. Psychosis in elderly patients: clas- sification and pharmacotherapy. J Geriatr Psychiatry Ne- urol 2003;16(4):199-206.
- Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced par- kinsonism. Mov Disord 1999;14(1):128-131.
- Kane JM, Correll CU. Pharmacologic treatment of schi- zophrenia. Dialogues Clin Neurosci 2010;12(3):345-357.
- Delay J, Deniker D, Drug induced extrapyramidal syndromes. In: Handbook of Neurology. Diseases of the Basal Ganglia, Vol 6, Editor: George W. Bruyn. The Net- herlands, North Holland Publishing Company, Amster- dam. 1968, pp. 248–266.
- Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23 Suppl 1:15-26.
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
- Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer an- tipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45.
- Gardoni F, Frasca A, Zianni E, Riva MA, Di Luca M, Fumagalli F. Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor com- position in rat striatum. Eur Neuropsychopharmacol 2008;18(7):531-534.
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38.
- Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater- blinded, prospective comparison: quetiapine versus clo- zapine for Parkinson’s disease psychosis. Clin Neurop- harmacol. 2006 Nov-Dec;29(6):331-337.
Abstract
References
- Bjarkam CR, Sİrensen JC, Sunde NA, Geneser FA, Oster- gaard K. New strategies for the treatment of Parkinson’s disease hold considerable promise for the future mana- gement of neurodegenerative disorders. Biogerontology 2001;2(3):193-207.
- Gárdián G, Vécsei L. Medical treatment of Parkinson’s disease: today and the future. Int J Clin Pharmacol Ther 2010;48(10):633-642.
- Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Prog Brain Res 2010;184:133-157.
- Langston WJ. The Impact of MPTP on Parkinson’s Dise- ase Research: Past, Present, and Future. In: Parkinson’s Disease. Diagnosis and Clinical Management. Editors: Stewart A. Factor and William J. Weiner, Demos Medical Publishing. New York. 2002, pp. 299-329.
- Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, Rungger G, Gasperi A, Willeit J, Poewe W. Prevalen- ce of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4(12):815-820.
- Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, Cardoso F. Parkinsonism and Parkinson’s disease in the elderly: a community- based survey in Brazil (the Bambuí study). Mov Disord 2006;21(6):800-808.
- Kuzuhara S. [Drug-induced parkinsonism]. Nippon Rinsho 1997;55(1):112-117.
- Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM; Neurological Disorders in Cent- ral Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly popula- tions of central Spain. Mov Disord 2003;18(3):267-274.
- Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, Walker A. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995;99(1):48-54.
- Mintzer J, Targum SD. Psychosis in elderly patients: clas- sification and pharmacotherapy. J Geriatr Psychiatry Ne- urol 2003;16(4):199-206.
- Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced par- kinsonism. Mov Disord 1999;14(1):128-131.
- Kane JM, Correll CU. Pharmacologic treatment of schi- zophrenia. Dialogues Clin Neurosci 2010;12(3):345-357.
- Delay J, Deniker D, Drug induced extrapyramidal syndromes. In: Handbook of Neurology. Diseases of the Basal Ganglia, Vol 6, Editor: George W. Bruyn. The Net- herlands, North Holland Publishing Company, Amster- dam. 1968, pp. 248–266.
- Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23 Suppl 1:15-26.
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
- Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer an- tipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45.
- Gardoni F, Frasca A, Zianni E, Riva MA, Di Luca M, Fumagalli F. Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor com- position in rat striatum. Eur Neuropsychopharmacol 2008;18(7):531-534.
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38.
- Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater- blinded, prospective comparison: quetiapine versus clo- zapine for Parkinson’s disease psychosis. Clin Neurop- harmacol. 2006 Nov-Dec;29(6):331-337.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | March 7, 2014 |
| Published in Issue | Year 2011 Volume: 15 Issue: 3 |
Cite
.